FP7Индивидуална стипендия2009–2011

STPRD · Significance of TDP-43 in the population in relation to dementia

7РП — „Хора“ (Действия „Мария Кюри“)

Период
2009-04-04 → 2011-09-03
Финансиране от ЕС
182 485 €
Участници
1
Схема
MC-IIF

Линиите свързват координатора с партньорите.

Накратко на български

Връзката между протеина TDP-43, генетиката и деменцията се анализира чрез данни за поведението и състоянието на мозъка. Резултатите помагат да се разбере как образованието в ранна възраст позволява на хората да се справят с мозъчните увреждания в старостта.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Significance of TDP-43 in the population in relation to dementia

Work carried out The fellow, Dr Keage, worked on a large database - 'Epidemiological clinicopathological studies in Europe' (Eclipse) (see http://www.eclipsestudy.eu online for further details) - to investigate the behavioural and biological correlates of a diagnosis of clinical dementia in late life and factors which affect its progression. Investigations made use of existing data within the Eclipse resource and new neuropathological data created during the Fellowship. This later neuropathological work was detailed in the original application. Further funding was required and successfully obtained from the Addenbrooke's Charity Trust, United Kingdom. Staining for, and scoring of, a new protein aggregate neuropathology of dementia, TDP-43, was carried out and results are soon to be reported in a series of papers in 2012. Notably, one paper published under this Fellowship (published in the journal Brain), received world-wide media attention including BBC TV and radio and Scientific American (over 250 online articles according to Google). This paper investigated how education in early life allows individuals to compensate for the presence of damage to the brain. Overview of results - Individuals who complete more education in early life are at lower risk of dementia in late life. This is not because they have fewer neuropathologies in their brain at death but rather, they are able to cognitively cope with the presence of these neuropathologies (Eclipse Collaborative Members, 2010). - A genetic polymorphism within the APOE gene is associated with cognitive decline over a long 10-year follow-up (Keage et al., 2010). - There is a complex relationship between obesity and dementia risk. Midlife obesity is strongly associated with dementia onset in late life, however late life obesity is protective (Keage et al., 2011). - Neuropathologies typically disregarded in terms of their importance to dementia in late life, along with rare pathologies thought to only play a role in rare early-onset dementias, contribute to the manifestation of clinical dementia in late life. The underlying neuropathology of late life dementia is more complex than originally thought (Keage et al., 2012). - Some sleep characteristics, particularly napping and excessive day time sleepiness, are predictive of cognitive decline in late life over a ten year time period (Keage et al., in press). - The significance of the new TDP-43 pathology to dementia in late life, associated symptomatology and neuropathology cannot be reported publically here as is under review at various scientific journals. Conclusions The underlying biology of late life dementia is complex, and is not simply due to the accumulation of amyloid and tau protein within the brain or vascular dysfunction. Further, although dementia only manifests in late life, its onset and progression is affected by health and behaviours over the entire life course. Socio-economic impacts of the project Results will improve our understanding of the pathological basis of late life dementia. Findings will feed most immediately into clinical diagnostic and prognostic applications, as well as in the development of biomarker and neuropathological diagnostic methods and new pharmacological treatments for late life dementia. Given our global aging population, this will be critical if we are to reduce the economic and social burdens of dementia in late life.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The incidence and prevalence of dementia is rising as the world-wide population ages. Determining biomarkers for the early detection of underlying biology that will predict dementia progression reliably or, the monitoring of biological processes once present to track progression and treatment is necessary. Furthermore, these biomarkers will aid in the differentiation of dementia from normal ageing and between its subtypes, and in the development of sensitive and specific diagnostic and treatment methods. The current study will be the first to assess a new protein-aggregating biomarker of dementia, TAR-DNA-binding-protein-43 (TDP-43), in a population-based sample. TDP-43 was implicated in the biology of dementia in 2006 however its relevance to the population is unknown. This study will assess the significance of TDP-43 in relation to dementia in a population sample of older people who have undergone brain donation. The sample (n=350) is from the European Clinicopathological Studies in Europe (EClipSE). Each participant has been tracked longitudinally for up to twenty years (dependent on date of death), with clinical (e.g., dementia and other diagnoses such as diabetes, cognition and psychological symptomatology) data available. The three study objectives are: • The determination of the prevalence of pathological TDP-43 expression in a population-based sample of older people as a whole and relative to dementia status. • The determination of the relationships between pathological TDP-43 expression and other neuropathological markers of dementia as well as longitudinal cognition and psychological symptomatology. • The development of clinical criteria which are sensitive and specific to the presence of pathological TDP-43 expression during life. These investigations will have significant implications for the diagnosis, management and treatment of dementia syndromes, with the aim of decreasing the social and economic costs of dementia.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз